Professor at University of Virginia, United States
Professional Profile
Education
Dr. Lian-Wang Guo’s educational background is rooted in biology and advanced plant physiology, providing a strong foundation for his extensive research career. He earned his Bachelor of Science degree in Biology from Xinjiang University in China in 1989, followed by a Master of Science in Plant Physiology from the prestigious Chinese Academy of Sciences in 1992. He continued his studies there, earning a Ph.D. in Plant Physiology and Biochemistry in 1995. Driven by a passion for genetics and biochemistry, Dr. Guo completed a postdoctoral fellowship at The Hebrew University of Jerusalem in 1998, where he broadened his research expertise in molecular biology. His educational journey reflects a commitment to understanding complex biological processes, which he has successfully applied to his pioneering work in vascular biology and epigenetics. Dr. Guo’s solid academic training has been instrumental in his innovative research contributions and leadership in biomedical sciences.
Dr. Lian-Wang Guo is a tenured Professor of Biomedical Sciences at the University of Virginia, specializing in vascular biology and epigenetics. With over 20 years of research experience, Dr. Guo has developed an expertise in chromatin modulators and their role in vascular diseases, particularly in neointima-associated restenosis. He has been continuously funded by the NIH since 2012, and his prolific contributions include 48 peer-reviewed publications and multiple patents, reflecting his leadership in vascular epigenetics research. His laboratory employs advanced molecular techniques such as ChIPseq, RNAseq, bioinformatics, and innovative nanoplatforms for targeted drug delivery. Dr. Guo has also successfully fostered clinical collaborations, including the development of therapeutic interventions currently undergoing large animal trials, with preparations for human studies. A dedicated mentor, he has cultivated a rigorous training environment for students and fellows, helping them transition into independent research careers. His research has garnered numerous awards and recognition from prominent scientific organizations.
Research Interests
Dr. Lian-Wang Guo’s extensive research contributions, particularly in vascular biology and epigenetics, position him as a leading scholar in biomedical sciences. His innovative work on chromatin modulators, specifically targeting epigenetic players like BRD4, EZH2, and DOT1L, has brought new insights into the treatment of neointimal-associated vascular diseases. Additionally, his development of nano-based, targeted drug delivery systems has shown promising translational potential, bridging the gap between basic science and clinical applications. With over 20 years of experience, numerous high-impact publications, NIH funding, and significant patents, Dr. Guo’s work is both cutting-edge and impactful. His mentorship of the next generation of scientists, as well as his collaborations with leading clinicians, further enhance his academic profile. While his contributions are already significant, a continued focus on clinical translation could maximize the impact of his research. Overall, Dr. Guo exemplifies the qualities of an outstanding researcher deserving of recognition.
- Article: Transmembrane protein TMEM97 and epigenetic reader BAHCC1 constitute an axis that supports pro-inflammatory cytokine expression
Authors: Li, J., Shen, H., Guo, L.-W.
Year: 2024
Citations: 0
- Article: miR579-3p is an inhibitory modulator of neointimal hyperplasia and transcription factors c-MYB and KLF4
Authors: Xie, X., Shirasu, T., Li, J., Guo, L.-W., Kent, K.C.
Year: 2023
Citations: 3
- Article: Neointima abating and endothelium preserving — An adventitia-localized nanoformulation to inhibit the epigenetic writer DOT1L
Authors: Shirasu, T., Yodsanit, N., Li, J., Gong, S., Guo, L.-W.
Year: 2023
Citations: 1
- Article: Targeted PERK inhibition with biomimetic nanoclusters confers preventative and interventional benefits to elastase-induced abdominal aortic aneurysms
Authors: Yodsanit, N., Shirasu, T., Huang, Y., Gong, S., Wang, B.
Year: 2023
Citations: 2
- Article: Gene-repressing epigenetic reader EED unexpectedly enhances cyclinD1 gene activation
Authors: Zhang, M., Li, J., Wang, Q., Miller, C.L., Guo, L.-W.
Year: 2023
Citations: 3
- Article: Sphingoid Bases Regulate the Sigma-1 Receptor—Sphingosine and N,N’-Dimethylsphingosine Are Endogenous Agonists
Authors: Li, J., Satyshur, K.A., Guo, L.-W., Ruoho, A.E.
Year: 2023
Citations: 3
- Article: Retinal Photoreceptor Protection in an AMD-Related Mouse Model by Selective Sigma-1 or Sigma-2 Receptor Modulation
Authors: Mavlyutov, T.A., Li, J., Liu, X., Pattnaik, B., Guo, L.-W.
Year: 2022
Citations: 4
- Erratum: Correction: miR548ai antagonism attenuates exosome-induced endothelial cell dysfunction (Cell Death Discovery, (2021), 7, 1, (318), 10.1038/s41420-021-00720-9)
Authors: Xie, X., Guo, L.-W., Kent, C.K.
Year: 2022
Citations: 0
- Article: Differential Responses to Sigma-1 or Sigma-2 Receptor Ablation in Adiposity, Fat Oxidation, and Sexual Dimorphism
Authors: Li, J., Félix-Soriano, E., Wright, K.R., Stanford, K.I., Guo, L.-W.
Year: 2022
Citations: 5
- Article: SREBP1 regulates Lgals3 activation in response to cholesterol loading
Authors: Li, J., Shen, H., Owens, G.K., Guo, L.-W.
Year: 2022
Citations: 9